Cowen Lowers Exagen (NASDAQ:XGN) Price Target to $7.00
Cowen Lowers Exagen (NASDAQ:XGN) Price Target to $7.00
Exagen (NASDAQ:XGN – Get Rating) had its price objective decreased by Cowen to $7.00 in a report released on Thursday, Stock Target Advisor reports. Cowen's price objective would suggest a potential upside of 138.10% from the stock's current price.
据Stock Target Advisor报道，在周四发布的一份报告中，埃克森美孚(纳斯达克：XGN-GET评级)的目标价被考恩下调至7.00美元。考恩的目标价格表明，该股目前的价格可能上涨138.10%。
A number of other research analysts have also recently issued reports on the company. Canaccord Genuity Group reduced their price objective on Exagen from $8.00 to $7.00 and set a "buy" rating on the stock in a research note on Tuesday. BTIG Research dropped their target price on shares of Exagen from $10.00 to $7.00 and set a "buy" rating for the company in a report on Thursday. KeyCorp lowered shares of Exagen from an "overweight" rating to a "sector weight" rating in a report on Friday, August 5th. Finally, Canaccord Genuity Group dropped their target price on shares of Exagen from $8.00 to $7.00 and set a "buy" rating for the company in a report on Tuesday. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Exagen has an average rating of "Moderate Buy" and an average target price of $9.60.
其他一些研究分析师最近也发布了关于该公司的报告。周二，Canaccel Genuity Group将Exagen的目标价从8.00美元下调至7.00美元，并在一份研究报告中设定了该股的“买入”评级。BTIG Research在周四的一份报告中将Exagen的目标价从10.00美元下调至7.00美元，并将该公司的评级定为“买入”。KeyCorp在8月5日星期五的一份报告中将Exagen的股票评级从“增持”下调至“行业权重”。最后，Canaccel Genuity Group在周二的一份报告中将Exagen的目标价从8.00美元下调至7.00美元，并将该公司的评级定为“买入”。一位研究分析师对该股的评级为持有，四位分析师对该公司的评级为买入。根据MarketBeat.com的数据，Exagen的平均评级为“中等买入”，平均目标价为9.60美元.
Exagen Stock Down 4.2 %
埃克森美孚股价下跌4.2%
Shares of NASDAQ:XGN opened at $2.94 on Thursday. The stock's 50-day moving average price is $2.92 and its 200-day moving average price is $4.79. Exagen has a 12-month low of $2.10 and a 12-month high of $12.89. The stock has a market capitalization of $47.80 million, a P/E ratio of -1.30 and a beta of 1.17. The company has a current ratio of 9.30, a quick ratio of 9.30 and a debt-to-equity ratio of 0.43.
纳斯达克：XGN周四开盘报2.94美元。该股的50日移动均线价格为2.92美元，200日移动均线价格为4.79美元。Exagen的12个月低点为2.10美元，12个月高位为12.89美元。该股市值为4780万美元，市盈率为-1.30，贝塔系数为1.17。该公司的流动比率为9.30，速动比率为9.30，债务权益比率为0.43。
Institutional Investors Weigh In On Exagen
机构投资者买入Exagen
Exagen Company Profile
Exagen公司简介
(Get Rating)
(获取评级)
Exagen Inc develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Exagen Inc.在美国开发和销售基于其细胞结合补体激活产品技术的各种测试产品，品牌为AVISE。它使风湿科医生能够通过自身免疫和自身免疫相关疾病的诊断、预后和监测来护理患者，包括系统性红斑狼疮(SLE)和类风湿性关节炎(RA)。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Exagen (XGN)
- MarketBeat: Week in Review 11/14 – 11/18
- Target's Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML's November Rally Have Staying Power?
- 免费获取StockNews.com关于Exagen的研究报告(XGN)
- MarketBeat：回顾一周11/14-11/18
- 目标的双重底部可能刚刚得到确认
- 美联储能涨到多高？如何进行交易
- Verra移动库存已返回空间站
- ASML的11月拉力赛有后劲吗？
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Exagen Daily》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Exagen和相关公司的最新新闻和分析师评级的每日简明摘要。
译文内容由第三方软件翻译。